Engrail Therapeutics Files for IPO Following $157M Oversubscribed Series B to Advance Precision Neurotherapeutics for Anxiety, Depression, and Rare Disorders

Drug R&D in the field of neuroscience has always been a highly complex and challenging endeavor. In recent years, the field of neuroscience has witnessed numerous new achievements.

As our understanding of the molecular and cellular mechanisms underlying neurological disorders deepens, scientists have been able to identify new therapeutic targets, providing fresh directions for drug development. This progress has also facilitated the broader application of precision medicine in this field, enabling the development of more personalized and effective treatment regimens through the identification of disease subtypes and biomarkers. Meanwhile, the discovery and validation of biomarkers have aided in early diagnosis, monitoring of disease progression, and assessment of drug efficacy, while advances in gene-editing technologies such as CRISPR have provided new tools for researching hereditary neurological diseases.

Despite significant advances in understanding diseases of the brain and nervous system, drug development for neuroscience continues to face a range of difficulties and challenges. Neurological disorders typically involve complex pathogenic mechanisms that engage multiple systems and pathways, making drug development particularly challenging. Furthermore, in terms of drug delivery, the blood-brain barrier (BBB) restricts the entry of many potential therapeutics, rendering the development of drug delivery systems a major challenge in neuroscience drug discovery.

Scientists and pharmaceutical companies are continually striving to overcome these challenges to develop new, more effective treatments that improve the quality of life for patients with neurological disorders, with Engrail Therapeutics being one such example.

Engrail Therapeutics, founded in 2019, is dedicated to improving the quality of life for patients with neurological disorders by providing translational therapies and acquiring pipeline assets with “validated mechanisms,” thereby overcoming challenges in neuroscience and delivering innovative, precisely targeted treatments.

In March 2024, Engrail Therapeutics completed a $157 million Series B financing round, co-led by F-Prime Capital, Forbion, and Norwest Venture Partners. The funds will be primarily used to conduct Phase II clinical trials of its pipeline candidate, ENX-102, for the treatment of patients with generalized anxiety disorder.

In 2020, as it launched its first clinical operations, Engrail Therapeutics raised $32 million in a Series A financing round. Led by Nan Fung Life Sciences (NFLS), the funding was primarily allocated to the development of its lead pipeline asset, the GABA-A modulator ENX-101.

In fact, Engrail Therapeutics’ heavily oversubscribed Series B financing is closely tied to the heightened interest in its industry and sector. Amidst the wave of acquisitions of neuroscience biotechnology companies by large pharmaceutical firms at the end of last year, investors have developed a strong interest in novel therapeutic approaches within the field of neuroscience. Since its establishment in 2019, Engrail Therapeutics has not only accumulated substantial expertise but also built a lean and highly experienced team, currently comprising 16 full-time employees and advisors.

Vikram Sudarsan, President and Chief Executive Officer, is a neuroscientist, investor, entrepreneur, and industry veteran with nearly 25 years of experience in the sector. Previously, Mr. Sudarsan served as CEO of Cipla Technologies, where he built a portfolio of branded products for the treatment of central nervous system (CNS) and respiratory diseases. In addition to his extensive expertise in neurological disorders, he possesses multifaceted proficiency in venture capital, business development, deal-making, market access, drug discovery, drug development, and operations.

Kimberly Vanover, Chief Scientific Officer at Engrail Therapeutics, brings over 25 years of industry experience in drug development for neuropsychiatric and neurodegenerative diseases. Previously, Ms. Vanover served as Senior Vice President of Clinical Development and Senior Vice President of Early Clinical Development and Translational Medicine at Intra-Cellular Therapies, where she guided the early development and regulatory approval of Caplyta (lumateperone) for the treatment of schizophrenia. Approved by the U.S. Food and Drug Administration (FDA) in 2020, Caplyta became the first and only once-monthly injectable antipsychotic medication to receive approval.

Furthermore, Quentin McCubbin, Chief Technology Officer at Engrail Therapeutics, has held significant responsibilities across various therapeutic areas. In the early stages of his career, he oversaw process chemistry at two biotechnology start-ups in the United Kingdom. Subsequently, he spent 19 years at Takeda Oncology, where he was responsible for active pharmaceutical ingredient (API) development, drug product development, analytical development, clinical supply, and quality operations. During this period, he supported the global approval of New Drug Applications (NDAs), Clinical Trial Applications (CTAs), and Biologics License Applications (BLAs) for four drugs: Adcetris, Entyvio, Ninlaro, and Relumina.

Engrail Therapeutics has earned strong market recognition and investor trust, thanks to its management team’s decades of deep expertise in neurological disorders combined with extensive managerial experience.

Engrail Therapeutics provides emerging therapies to patients in need, grounded in scientifically validated mechanisms of action and established proof-of-concept. The company is currently focused on developing novel drugs for anxiety and depression by targeting GABA and dopamine modulation mechanisms.

• GABA Modulation and ENX-102

In the treatment of anxiety disorders, GABA (γ-aminobutyric acid) serves as the primary inhibitory neurotransmitter in the central nervous system, playing a crucial role in regulating neuronal excitability. The mechanism of GABA regulation involves the activity of GABA receptors, which are located on neurons in the brain and spinal cord and are classified into GABA-A and GABA-B receptors. Modulation of the GABA system is of significant importance for treating various neurological conditions, including anxiety, depression, epilepsy, and other neurodegenerative diseases.

Engrail’s research expertise lies in GABA receptor pharmacology and neural circuits, facilitating the development of precision-targeted therapies for anxiety disorders that maximize the clinical benefits of GABA modulation while minimizing the adverse side effects and risks associated with benzodiazepines.

Based on the GABA modulation mechanism, Engrail Therapeutics has developed ENX-102, a next-generation, precisely targeted GABAA positive allosteric modulator for the treatment of generalized anxiety disorder (GAD). It is currently undergoing a Phase 2 multicenter clinical trial as monotherapy in patients with GAD.

Currently, generalized anxiety disorder (GAD) is a significant public health concern. Although more than 5.4 million Americans are receiving treatment for GAD, many patients respond poorly to first- or second-line therapies, thereby facing risks of complications, relapse, and poor treatment adherence. Even among patients who do respond to treatment, it may take months to experience improvement in anxiety symptoms. ENX-102 has been developed to address these challenges by offering a new therapeutic option. Previous clinical trials have demonstrated that ENX-102 not only exhibits a rapid onset of action and sustained efficacy, but also features a favorable safety and tolerability profile. This represents a significant advantage for patients requiring prompt relief from anxiety symptoms, while its sustained efficacy helps patients better manage their symptoms and reduces the risk of treatment discontinuation.

• Dopamine Modulation and ENX-104, ENX-105

In the treatment of depression, dopamine is an important neurotransmitter that functions in multiple brain regions, including those involved in mood regulation, reward perception, cognitive function, and motor control. Dysregulation of dopamine is considered a key factor in the pathogenesis of depression. Currently, many antidepressant medications affect the dopaminergic system in various ways.

Based on dopamine modulation mechanisms, Engrail has developed ENX-104, a potent D2/D3 receptor antagonist that supports once-daily dosing for the treatment of major depressive disorder (MDD).

Compared with existing medications for the treatment of major depressive disorder (MDD), ENX-104 offers several potential advantages. First, by specifically targeting D2/D3 receptors, it can more precisely modulate neurotransmission associated with anhedonia. Second, ENX-104 is developed to directly address anhedonia, a core symptom of MDD that is often inadequately managed by current therapies. Additionally, the pharmacokinetic profile of ENX-104 supports once-daily dosing, which can significantly improve patient adherence and therapeutic outcomes. Furthermore, ENX-104 has demonstrated favorable safety and tolerability in preclinical studies.

In addition to focusing on major depressive disorder, Engrail also pays attention to other mood disorders. Its developed ENX-105 has a unique mechanism of action, combining potent D2/D3 receptor antagonism with serotonin modulation. Engrail is conducting extensive analyses to determine the clinical indication priorities for ENX-105, which may include bipolar disorder, anxious depression, post-traumatic stress disorder, and other stress-related mood disorders.

Currently, Engrail Therapeutics has expanded its portfolio beyond neurological disorders to include rare diseases. Its novel copper-transporting small molecule, ENX-105, is in the preclinical development stage for the treatment of Menkes syndrome. Menkes syndrome is caused by a defect in copper transport resulting from mutations in the ATP7A gene. This defect leads to abnormal copper distribution throughout the body, characterized by severe copper deficiency in the brain and copper accumulation in other organs such as the intestines and kidneys. Clinical features include severe neurodegenerative changes, hypotonia, connective tissue abnormalities, hypopigmentation, and kinky hair.

ENX-105, developed by Engrail Therapeutics, facilitates the transport of copper from biofilms into mitochondria, a process that is particularly critical for healthy brain development. In preclinical studies, ENX-105 rescued neonatal lethality in Menkes disease model mice, extended survival, and supported neurodevelopment.

Although Engrail Therapeutics has garnered favor from investors in its fundraising efforts, it is worth noting that despite recent advances in the field of neurological diseases, a significant number of drug candidates fail in clinical trials. Many therapies face substantial hurdles or the risk of clinical trial failure. Furthermore, neuroscience drug development typically requires long-term investment; the journey from early-stage research to final market approval can span decades. While Engrail Therapeutics’ drug candidates hold the potential to provide new treatments for patients with neurological disorders, the path forward remains arduous and will require further clinical validation and data support.